ER/LA opioid analgesics

Published on:
Monday, May 8, 2017

This report contains explanations and examples of the types of data that ACCME has collected about ER/LA Opioid REMS continuing education provided by ACCME and SMS-accredited providers.

Published on:
Thursday, April 20, 2017

The ACCME submitted a letter to Sen. McCaskill, Ranking Member, Committee on Homeland Security and Governmental Affairs, to address her investigation of the opioid epidemic. In the letter, Graham McMahon, MD, MMSc, President and...

Published on:
Friday, September 9, 2016

The ACCME submitted these comments to the US Department of Health and Human Services (HHS) in response to HHS’ request for information about opioid analgesic prescriber education and training opportunities to prevent opioid...

Published on:
Tuesday, December 16, 2014

The ACCME sent this letter in response to the Food and Drug Administration (FDA) report Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS). The letter offers observations and suggestions for...

Published on:
Friday, November 22, 2013

The FDA has provided the following description of the REMS Long-Term Evaluations in its ER/LA Opioid Analgesics REMS Supporting Document:

“A subset of CE providers capable of conducting evaluations of long-term performance...

Published on:
Friday, November 22, 2013
  • CME in Support of REMS: This ACCME Web Page provides updates and resources for accredited CME providers that...
Published on:
Friday, November 22, 2013

For the ER/LA Opioid Analgesics REMS, the FDA writes that: Training will be...

Published on:
Friday, November 22, 2013

The RPC has hired inVentiv Health, Ltd. to manage the commercial support. So, in this complicated case, for simplicity, the accreditor is allowing providers to specify the “RPC/inVentiv Health, Ltd.” as the commercial supporter....

Published on:
Friday, November 22, 2013

The REMS Program Companies (RPC) are responsible to the FDA for fulfilling the requirements for long-term evaluations.  The RPC will provide funding to...

Published on:
Friday, November 22, 2013

Accredited CME providers that are interested in conducting the long-term evaluations might provide service in support of the ER/LA Opioid Analgesics REMS in the following ways:

  1. Providers can...

Since 2009, the ACCME has supported the role of accredited CME as a strategic asset to US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS), provided the proper...

FDA REMS Meetings, Fact Sheet for CME Providers

The ACCME has participated in two meetings with the Food and Drug Administration (FDA) about Risk Evaluation and Mitigation Strategies (REMS). We...

The ACCME has released a data report showing the scope of continuing...

Report Shows REMS-Compliant CE Activities Reach 70,000 Healthcare Professionals

The ACCME has released a ...

The ACCME submitted a comment to the US Department of Health and Human...

PARS Modifications Support REMS Data Collection and Auditing Process

...

Here are additional resources to support accredited CME providers that choose to design education to address the goals of the FDA Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and...

Meeting Describes Value of CE in Supporting FDA REMS

Kate Regnier, MA, MBA, Executive Vice President, ACCME, attended the joint meeting of the Conjoint Committee on Continuing...

An improved web-based tool to search for CME opportunities is now available on the ACCME website. This tool provides information for each accredited CME activity that...

CE Accreditors Respond to FDA REMS Proposal

The ACCME, the ...

Physician Leaders Address Role of CE in REMS

Kim Edward LeBlanc, MD, PhD, Chair, ACCME Board of Directors; Victor Reus, MD, Vice Chair, ACCME Board of Directors; and Graham McMahon,...

Presentation about CE's role in ER/LA Opioid Analgesics REMS

The ...

Pages